Drug intelligence / Profile preview

SBT-550

Development stage: Discontinued
Lead developer: Stealth BioTherapeutics
Modality: Small Molecules

Overview

SBT-550 is a series of novel small molecules developed by Stealth BioTherapeutics as mitochondria-targeted therapeutics designed to address mitochondrial dysfunction in rare neurological diseases. Following promising preclinical data, the company has indicated plans to evaluate these compounds for rare neurodegenerative and ophthalmic disease indications, leveraging an optimized discovery platform to identify compounds that may serve as therapeutic candidates or delivery vectors for other mitochondria-targeted agents.[1][3][12]

Beyond the preview

Go deeper on SBT-550.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBT-550.

Explore the full profile